Safety of materials and products already starts at the design phase The Ministry of Infrastructure and Water Management aims to ensure that all new materials and technological developments are safe in 2050.
Launch of the European project RISK-HUNT3R The new Horizon 2020 project RISK-HUNT3R: RISK assessment of chemicals integrating HUman centric Next generation Testing strategies promoting the 3Rs was launched on 1 June.
Largest drop in number of tuberculosis cases in the Netherlands in fifty years Last year, the incidence of tuberculosis (TB) in the Netherlands fell sharply. The 17% drop is the largest in fifty years. In 2020, 623 cases were notified compared to 754 in 2019.
A decrease in the number of tuberculosis patients in the Netherlands In 2019, the number of people with tuberculosis (TB) in the Netherlands decreased to 759. This is 5 per cent less than in 2018, when 797 were reported.
Air quality Sint Maarten landfill At the beginning of 2019, RIVM measured the air quality around the landfill at Philipsburg, Sint Maarten for two weeks. No or hardly any harmful substances were measured.
Slightly more tuberculosis patients in the Netherlands The key figures of the National Institute for Public Health and the Environment (RIVM) show that in 2018 there were 806 TB patients in the Netherlands. This is 3 percent more than in 2017 (784).
RIVM will make measurements around the Sint Maarten landfill From 21 January 2019, a team from RIVM will travel to Sint Maarten to make measurements and take samples at various locations around the landfill in Philipsburg.
Biosafety and Biosecurity on the Global Health Security Agenda Since 2018, the Netherlands leads the way in the field of "Biosafety and Biosecurity" within the international Global Health Security Agenda (GHSA).
Strong decline of tuberculosis in the Netherlands The number of tuberculosis (TB) patients in the Netherlands decreased considerably in 2017. From 887 patients in 2016 to 787 in 2017.
Global Infectious Disease Control hampered by the CBD Nagoya Protocol So far, none of the models used by international networks of biobanks to arrange the legal responsibility under the CBD-Nagoya protocol works efficiently.